T. Rowe Price Investment Management’s Edwards Lifesciences EW Stock Holding History

T. Rowe Price Investment Management’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1,929	Closed	-$165K	–	744
2025 Q4	$165K	Sell	1,929 -577	-23%	-$47.4K	﹤0.01%	658
2025 Q3	$195K	Buy	2,506 +416	+20%	+$32.5K	﹤0.01%	658
2025 Q2	$164K	Buy	+2,090	New	+$156K	﹤0.01%	657
2024 Q1	–	Sell	-1,249	Closed	-$96K	–	633
2023 Q4	$96K	Buy	+1,249	New	+$86.9K	﹤0.01%	585

Other funds holding EW

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

T. Rowe Price Investment Management's EW Position: Q1 2026 in Review

T. Rowe Price Investment Management sold out of Edwards Lifesciences (EW) in Q1 2026, closing a stake of 1,929 shares — an estimated $165K sold.

T. Rowe Price Investment Management first reported a position in EW in Q4 2023 and held it in 4 quarters. The position peaked at $195K in Q3 2025. 1,288 funds tracked by Wall St. Rank hold EW as of Q1 2026.

T. Rowe Price Investment Management reported no remaining Edwards Lifesciences position as of Q1 2026 after selling out during the quarter.
T. Rowe Price Investment Management sold 1,929 Edwards Lifesciences shares in Q1 2026, an estimated $165K.
T. Rowe Price Investment Management first reported a position in Edwards Lifesciences in Q4 2023 and held it in 4 quarters.
T. Rowe Price Investment Management's Edwards Lifesciences position peaked at $195K in Q3 2025.
1,288 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.

Based on T. Rowe Price Investment Management's 13F filing for Q1 2026, filed 15 May 2026.